Paige Predict Marks Tempus AI’s Next Leap in Cancer Insight

Tempus AI expands multimodal data and launches Paige Predict to refine cancer diagnostics and drug development

2 Feb 2026

Precision medicine has promised a lot over the past decade. Turning that promise into everyday clinical reality has been harder. Tempus AI believes the gap can be closed by making complex medical data easier to connect, read, and act on.

Rather than focusing on a single data stream, Tempus has built one of the industry’s largest multimodal datasets. It combines genomic sequencing, clinical records, and medical imaging, then layers artificial intelligence on top to generate insights clinicians can actually use.

The problem it is tackling is familiar across healthcare. New tools have flooded the system with information, from digital pathology scans to electronic health records. But these systems rarely talk to one another. The result is data-rich environments that still struggle to support timely decisions.

Tempus is betting that integration matters more than volume. Its platform is designed to bring disparate data types into a single workflow, where machine learning models are trained for specific clinical and research tasks instead of broad experimentation.

A major step came in January 2026 with the launch of Paige Predict. The product grew out of Tempus’s acquisition of digital pathology company Paige the year before. Paige Predict analyzes routine H&E pathology slides and estimates the likelihood that certain cancer biomarkers are present.

The goal is not to replace molecular testing but to guide it. When tissue samples are limited, the tool can help clinicians decide which follow-up tests are most urgent, potentially cutting down on delays and repeat procedures.

This focus on pathology reflects a broader push by Tempus to link images with genomic profiles and long-term patient records, especially in cancer care. Subtle biological differences can shape treatment response, and tighter data connections may improve therapy selection and clinical trial matching.

Partnerships also play a role. Tempus has worked with health systems like Northwestern Medicine to integrate its AI tools directly into electronic health record workflows. The emphasis is on fitting into existing infrastructure, not standing apart from it.

There are still hurdles, including regulatory scrutiny, data privacy concerns, and demands for transparency in AI-driven decisions. Even so, with tools like Paige Predict and continued investment in connected data, Tempus AI is helping push precision medicine from theory toward routine practice.